Evommune EVMN Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | ||
|---|---|---|---|---|
| $6.67M+0.8% | $6.61M-2.7% | $6.8M+4.6% | ||
| $3.09M-1.3% | $3.13M+4.4% | $2.99M+2.9% | ||
| $3.58M+2.7% | $3.48M-8.4% | $3.8M+6.0% | ||
| 53.7%+1.0pp | 52.7%-3.3pp | 55.9%+0.7pp | ||
| $717.49K+13.5% | $632.41K+8.3% | $584.15K-6.1% | ||
| $4.91M+15.5% | $4.25M+17.4% | $3.62M+3.2% | ||
| $5.63M+15.3% | $4.88M+16.1% | $4.2M+1.8% | ||
| -$2.05M-46.5% | -$1.4M-248% | -$401.57K+25.9% | ||
| -30.7%-9.6pp | -21.2%-15.2pp | -5.9%+2.4pp | ||
| $333.11K-17.2% | $402.4K-13.2% | $463.7K+22.7% | ||
| —— | —— | —— | ||
| —— | —— | —— | ||
| -$2.05M-46.5% | -$1.4M-248% | -$401.57K+25.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Evommune 's revenue?
- Evommune (EVMN) generated $6.7M in revenue over the trailing twelve months.
- Is Evommune profitable?
- Evommune is not currently profitable: it reported a net loss of $6.0M over the trailing twelve months, a -90.1% net margin.
- What are Evommune 's profit margins?
- Gross margin is 53.7% and operating margin is -30.7%, with a -90.1% net margin.
- What is Evommune 's earnings per share?
- Evommune 's diluted EPS over the trailing twelve months is $-0.32.
- Where does Evommune 's income statement data come from?
- Every line is extracted from Evommune 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
